ArticleThe journal of nutrition, health & aging2026
Association between accelerated biological aging and major adverse cardiovascular events in patients with stable coronary artery disease.
Article in The journal of nutrition, health & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccelerated biological aging is characterized by an expedited deterioration of physiological systems. Phenotypic age (PA) derived from chronological age and 9 clinical biomarkers serves as a robust measure of this process, and phenotypic aging acceleration (PAA) was the discrepancy between phenotypic and chronological age. However, its association with major adverse cardiovascular events (MACEs) in stable coronary artery disease (SCAD) remains unclear.
methodsThis cohort study enrolled 8672 patients with SCAD who underwent initial percutaneous coronary intervention (PCI). Accelerated biological aging was assessed using phenotypic aging calculations, and MACEs were defined as death (all-cause and cardiac mortality), non-fatal myocardial infarction (MI), non-fatal stroke, and unplanned revascularization. A cox proportional hazard model was employed for analysis.
resultsOverall, the subjects were 64.7 ± 6.5 years old while the PA were 62.7 ± 12.3 years and the PAA was -2.8 (-6.4, 1.5) years. During overall 2.2 (1.4, 3.1) follow up years, 1147 MACEs were documented (165 all-cause mortality, 47 cardiac mortality, 918 unplanned revascularization, 43 non-fatal MI and 80 non-fatal strokes). Compared with phenotypically younger group (PAA < 0), phenotypically older group (PAA ≥ 0) showed higher risk for MACEs and components (all P values < 0.05). A positive dose-response association was identified between PAA and MACEs. For each 1-year PAA, there were 2.80%, 8.80%, 10.80%, 1.20%, 5.80%, 4.50% higher risk of MACEs, all-cause mortality, cardiac mortality, unplanned revascularization, non-fatal MI and non-fatal stroke, respectively (all P values < 0.05). Robust results were demonstrated in subgroup analysis.
conclusionIn SCAD patients undergoing PCI, accelerated biological aging is associated with an increased risk of MACEs, particularly death (all-cause and cardiac mortality) and unplanned revascularization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.